Document Detail


Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation.
MedLine Citation:
PMID:  6191299     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fifty-eight patients with symptomatic ventricular tachycardia (VT) or ventricular fibrillation (VF) were treated with amiodarone. All had clinical episodes of VT/VF or inducible VT during electropharmacologic testing despite treatment with maximum-tolerated doses of conventional antiarrhythmic agents. Chronic treatment with amiodarone was begun at a dose of 800-1000 mg per day. Thirty-two patients were also treated with a previously ineffective conventional agent. Thirty patients underwent programmed ventricular stimulation after 2.6 +/- 1.7 months (mean +/- S.D.) of treatment with amiodarone at a mean daily dose of 588 +/- 155 mg. VT was induced in 25 patients (sustained in 20, nonsustained in five). Seventeen patients had a recurrence of VT or VF after 0.5-9 months of treatment with amiodarone (fatal in seven, non-fatal in 10). Forty-one patients (71%) had no recurrence of symptomatic VT or VF while being treated with amiodarone (mean follow-up period, 17.1 +/- 12.4 months). Among the 25 patients who had inducible VT with programmed ventricular stimulation while being treated with amiodarone, 19 patients (76%) have had no recurrence of symptomatic VT or VF over a follow-up period of 21.5 +/- 7.3 months. Ambulatory electrocardiographic recordings obtained after one week of treatment with amiodarone were not helpful in predicting clinical response. Twenty-two patients (38%) developed ataxia and/or an intention tremor which improved with a decrease in the amiodarone dose. Amiodarone, either by itself or in combination with conventional antiarrhythmic drugs, has a significant therapeutic effect in high risk patients with refractory VT. The finding of inducible VT during electropharmacologic testing in patients taking amiodarone does not preclude a favorable clinical response. Neurologic toxicity is common in patients treated with 600-800 mg per day of amiodarone.
Authors:
F Morady; M M Scheinman; D S Hess
Related Documents :
3146989 - Flecainide compared with a combination of digoxin and disopyramide for acute atrial arr...
16267249 - Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake.
21925869 - Neuraxial blockade for external cephalic version: a systematic review.
2929439 - Signal-averaged electrocardiography in the time and frequency domains.
15797279 - Effect of hypothermia on transthoracic defibrillation in a swine model.
3789859 - Long-term efficacy of subendocardial resection in refractory ventricular tachycardia: r...
24719039 - Short apical rib resections thoracoplasty compared to conventional thoracoplasty in ado...
11103179 - Effects of amrinone on ischaemia-reperfusion injury in cirrhotic patients undergoing he...
20103509 - A prospective randomized multicenter trial shows improvement of sternum related complic...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  6     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  1983 May 
Date Detail:
Created Date:  1983-08-17     Completed Date:  1983-08-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  609-15     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amiodarone / adverse effects,  therapeutic use*
Benzofurans / therapeutic use*
Cardiac Pacing, Artificial
Electrocardiography
Female
Heart Rate / drug effects
Heart Ventricles / drug effects
Humans
Male
Middle Aged
Tachycardia / drug therapy*
Ventricular Fibrillation / drug therapy*
Chemical
Reg. No./Substance:
0/Benzofurans; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Atrial synchronized ventricular pacing: contribution of the chronotropic response to improved exerci...
Next Document:  Assessment of atrial capture in committed atrioventricular sequential (DVI) pacing systems.